Prevention of Musculoskeletal Pain With Etoricoxib for Breast Cancer Patients Receiving Docetaxel Chemotherapy and Pegfilgrastim

• Status: Completed
• Trial end date: 2021-06-28

Summary

Breast cancer patients who received docetaxel chemotherapy and prophylactic use of pegfilgrastim were randomly divided into two groups; experimental group: prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8); control group: no prophylactic regimen was given. Primary endpoint: overall incidence of musculoskeletal pain across all cycles of chemotherapy. Secondary endpoints: incidence, severity and duration of musculoskeletal pain at each cycle; incidence of severe musculoskeletal pain (score, defined as greater than 5 on a scale from 0 to 10) by cycle and across all cycles; Functional Assessment of Cancer Therapy-Breast (FACT-B) subscale at each cycle; incidence of peripheral neuropathy after all cycles of chemotherapy; adverse events.

• Phase: Phase 2

Details

• Lead Sponsor: Guangdong Provincial People's Hospital
• Treatments: Etoricoxib